Rheumatoid Arthritis Market is expected to increase from $56.6 billio Rheumatoid Arthritis Market 2020 | Page 8

7.1.6 Ablynx enters into a licensing deal with Abbvie for the Nanobody ALX-006 87
7.2 Co-development 88
7.2.1 Deal Values by Therapeutic Molecule Types and Phase 89
7.2.2 Deal Values by Therapeutic mechanism of administration and Phase 91
7.2.3 GlaxoSmithKline enters into Global Agreement with Archemix 93
7.2.4 Abbott Laboratories Enters into Global Collaboration with Galapagos for filgotinib 93
7.2.5 Chroma Therapeutics Enters into a Co-development Agreement with GlaxoSmithKline 93

8 Appendix 94
8.1 All Pipeline Drugs by Phase of Development 94
8.1.1 Discovery 94
8.1.2 Preclinical 98
Read Complete Report with TOC @ http://www.radiantinsights.com/research/rheumatoidarthritis-market-to-2020-a-crowded-market-characterized-by-modest-growth
8.1.3 IND-CTA Filed 108
8.1.4 Phase I 109
8.1.5 Phase II 111
8.1.6 Phase III 113
8.2 Market Forecasts to 2020 115
8.3 Abbreviations 119
8.4 References 120
8.4.1 References for Error! Reference source not found. 132
8.4.2 References for Figure 32 134
8.5 Research Methodology 135
8.5.1 Secondary Research 136
8.5.2 Marketed Product Profiles 136